Arcutis Biotherapeutics (ARQT) Cash from Financing Activities (2019 - 2026)
Arcutis Biotherapeutics (ARQT) posted quarterly Cash from Financing Activities of $1.1 million for Q1 2026, up 170.13% year-over-year from $395000.0 in Q1 2025, and down 71.33% quarter-over-quarter from $3.7 million in Q4 2025.
Arcutis Biotherapeutics (ARQT) Cash from Financing Activities (2019 - 2026) Analysis & Trends
Arcutis Biotherapeutics' Cash from Financing Activities history runs 8 years deep, the most recent figure standing at $1.1 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 170.13% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $7.6 million (up 108.03% YoY), while the FY2025 annual figure was $7.0 million, down 89.47% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $1.1 million, down from $3.7 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $285.0 million in Q3 2022, with the low at -$97.4 million in Q4 2024.
- The 5-year median for Cash from Financing Activities is $1.1 million (2022), against an average of $28.1 million.
- The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities soared 452263.49% in 2022, then plunged 198.11% in 2024.
- Arcutis Biotherapeutics' Cash from Financing Activities stood at $962000.0 in 2022, then surged by 10221.1% to $99.3 million in 2023, then slumped by 198.11% to -$97.4 million in 2024, then soared by 103.82% to $3.7 million in 2025, then slumped by 71.33% to $1.1 million in 2026.
- Business Quant data shows ARQT's Cash from Financing Activities at $1.1 million in Q1 2026, $3.7 million in Q4 2025, and $1.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Arcutis Biotherapeutics | 3.29 Bn | 3.05 Bn | 118.92 Mn | 1.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.99 Mn |
| Jun 30, 2026 | 1.99 Mn |
| Mar 31, 2026 | 1.07 Mn |
| Mar 31, 2026 | 1.07 Mn |
| Dec 31, 2025 | 3.72 Mn |
| Dec 31, 2025 | 3.72 Mn |
| Sep 30, 2025 | 1.48 Mn |
| Sep 30, 2025 | 1.48 Mn |
| Jun 30, 2025 | 1.38 Mn |
| Jun 30, 2025 | 1.38 Mn |
| Mar 31, 2025 | 395,000.00 |
| Mar 31, 2025 | 395,000.00 |
| Dec 31, 2024 | -97.41 Mn |
| Dec 31, 2024 | -97.41 Mn |
| Sep 30, 2024 | 394,000.00 |
| Sep 30, 2024 | 394,000.00 |
| Jun 30, 2024 | 1.46 Mn |
| Jun 30, 2024 | 1.46 Mn |
| Mar 31, 2024 | 161.76 Mn |
| Mar 31, 2024 | 161.76 Mn |